Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model

Xia,Li‑Jie; Wu,Yan‑Ling; Ma,Ji; Zhang,Fu‑Chun

doi:10.3892/mmr.2018.8691

Therapeutic effects of antimicrobial peptide on malignant ascites in a mouse model

Authors:
- Li‑Jie Xia
- Yan‑Ling Wu
- Ji Ma
- Fu‑Chun Zhang
View Affiliations

Affiliations: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang 830046, P.R. China
Published online on: March 7, 2018 https://doi.org/10.3892/mmr.2018.8691
Pages: 6245-6252
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The primary objective of the treatment of malignant ascites in advanced stages is to alleviate symptoms using procedures such as diuresis, paracentesis of subretinal fluid and vena cava anastomosis. The effectiveness of systemic or intraperitoneal chemotherapy treatment is limited, and more efficacious therapies are required. The authors of the present study demonstrated that an antimicrobial peptide, cecropinXJ, isolated from the larvae of Bombyx mori, selectively inhibits the proliferation of gastric cancer cells. However, the effects of antibacterial peptides on gastric ascites tumor remains unclear. In the present study, the therapeutic effects of cecropinXJ were investigated in mice bearing malignant ascites. Compared with bovine serum albumin treatment, cecropinXJ and doxorubicin (Dox) significantly inhibited the formation and growth of malignant ascites, and prolonged the survival time of ascites tumor‑bearing mice. In addition, cecropinXJ treatment normalized the hematological and biochemical phenotypes, induced tumor cell apoptosis in ascites and improved the survival of mice bearing malignant ascites when compared with Dox treatment. These results suggested that cecropinXJ might be a promising therapeutic candidate for the treatment of gastric cancer‑associated ascites.

View Figures

View References

1	Parsons SL, Watson SA and Steele RJ: Malignant ascites. Br J Surg. 83:6–14. 1996. View Article : Google Scholar : PubMed/NCBI
2	Runyon BA: Care of patients with ascites. N Engl J Med. 330:337–342. 1994. View Article : Google Scholar : PubMed/NCBI
3	Sasako M: Principles of surgical treatment for curable gastric cancer. J Clin Oncol. 21 23 Suppl:274s–275s. 2003. View Article : Google Scholar : PubMed/NCBI
4	Becker G, Galandi D and Blum HE: Malignant ascite: Systematic review and guideline for treatment. Eur J Cancer. 42:589–597. 2006. View Article : Google Scholar : PubMed/NCBI
5	Smith EM and Jayson GC: The current and future management of malignant ascites. Clin Oncol (R Coll Radiol). 15:59–72. 2003. View Article : Google Scholar : PubMed/NCBI
6	Cruciani RA, Barker JL, Zasloff M, Chen HC and Colamonici O: Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. Proc Natl Acad Sci USA. 88:pp. 3792–3796. 1991; View Article : Google Scholar : PubMed/NCBI
7	Jin XB, Li XB, Zhu JY, Lu XM, Shen J, Chu FJ and Mei HF: The target of Musca domestica cecropin on human hepatocellular carcinoma BEL-7402 cells. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 29:271–273. 2011.(In Chinese). PubMed/NCBI
8	Jin XB, Wang YJ, Liang LL, Pu QH, Shen J, Lu XM, Chu FJ and Zhu JY: Cecropin suppresses human hepatocellular carcinoma BEL-7402 cell growth and survival in vivo without side-toxicity. Asian Pac J Cancer Prev. 15:5433–5436. 2014. View Article : Google Scholar : PubMed/NCBI
9	Liu Z, Zhang F, Cai L, Zhao G and Wang B: Studies on the properties of cecropin-XJ expressed in yeast from Xinjiang silkworm. Wei Sheng Wu Xue Bao. 43:635–641. 2003.(In Chinese). PubMed/NCBI
10	Xia L, Zhang F, Liu Z, Ma J and Yang J: Expression and characterization of cecropinXJ, a bioactive antimicrobial peptide from Bombyx mori (Bombycidae, Lepidoptera) in Escherichia coli. Exp Ther Med. 5:1745–1751. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xia L, Liu Z, Ma J, Sun S, Yang J and Zhang F: Expression, purification and characterization of cecropin antibacterial peptide from Bombyx mori in Saccharomyces cerevisiae. Protein Expr Purif. 90:47–54. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wu YL, Xia LJ, Li JY and Zhang FC: CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo. Int J Oncol. 46:2181–2193. 2015. View Article : Google Scholar : PubMed/NCBI
13	Xia L, Wu Y, Kang S, Ma J, Yang J and Zhang F: CecropinXJ, a silkworm antimicrobial peptide, induces cytoskeleton disruption in esophageal carcinoma cells. Acta Biochim Biophys Sin (Shanghai). 46:867–876. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wu Y, Xia L and Zhang F: Inhibition of CecropinXJ on proliferation of human gastric cancer AGS cells. Chin J Cell Biol. 36:1355–1361. 2014.(In Chinese).
15	Fung KY, Ooi CC, Zucker MH, Lockett T, Williams DB, Cosgrove LJ and Topping DL: Colorectal carcinogenesis: A cellular response to sustained risk environment. Int J Mol Sci. 14:13525–13541. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lettre H: Tests of compounds against the Ehrlich mouse ascites tumor. Cancer Res. 2 Suppl:S125–S128. 1955.
17	Sugiura K: Effect of various compounds on the Ehrlich ascites carcinoma. Cancer Res. 13:431–441. 1953.PubMed/NCBI
18	Dagistan Y, Dagistan E and Citisli V: Evaluation of simple blood counts as inflammation markers for brain tumor patients. Neurol Neurochir Pol. 50:231–235. 2016.PubMed/NCBI
19	Sedláková O, Sedlák J, Hunáková L, Jakubíková J, Duraj J, Sulíková M, Chovancová J and Chorváth B: Angiogenesis inhibitor TNP-470: Cytotoxic effects on human neoplastic cell lines. Neoplasma. 46:283–289. 1999.PubMed/NCBI
20	Yoshizawa J, Mizuno R, Yoshida T, Hara A, Ashizuka S, Kanai M, Kuwashima N, Kurobe M and Yamazaki Y: Inhibitory effect of TNP-470 on hepatic metastasis of mouse neuroblastoma. J Surg Res. 93:82–87. 2000. View Article : Google Scholar : PubMed/NCBI
21	Oey RC, van Buuren HR and de Man RA: The diagnostic work-up in patients with ascites: Current guidelines and future prospects. Neth J Med. 74:330–335. 2016.PubMed/NCBI
22	Sostelly A, Henin E, Chauvenet L, Hardy-Bessard AC, Jestin-Le Tallec V, Kirsher S, Leyronnas C, Ligeza-Poisson C, Ramdane S, Salavt J, et al: Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO. J Geriatr Oncol. 4:48–57. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zolfagharzadeh F and Roshan VD: Pretreatment hepatoprotective effect of regular aerobic training against hepatic toxicity induced by Doxorubicin in rats. Asian Pac J Cancer Prev. 14:2931–2936. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hogland HC: Hematologic complications of cancer chemotherapy. Semin Oncol. 9:95–102. 1982.PubMed/NCBI
25	Arora S, Jain J, Rajwade JM and Paknikar KM: Cellular responses induced by silver nanoparticles: In vitro studies. Toxicol Lett. 179:93–100. 2008. View Article : Google Scholar : PubMed/NCBI
26	Maseki M, Nishigaki I, Hagihara M, Tomoda Y and Yagi K: Lipid peroxide levels and lipids content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. Clin Chim Acta. 115:155–161. 1981. View Article : Google Scholar : PubMed/NCBI
27	Verhaeghe L, Bruyneel L, Stragier E, Ferrante M, Dierickx D and Prenen H: The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study. Ann Gastroenterol. 30:654–663. 2017.PubMed/NCBI
28	Dong JF, Zheng XQ and Rui HB: Effect of taurine on immune function in mice with T-cell lymphoma during chemotherapy. Asian Pac J Trop Med. 10:1090–1094. 2017. View Article : Google Scholar : PubMed/NCBI